Mr Karnik Parikh,
director Pharmalab, Maharashtra
Mumbai-based Pharmalab, is an engineering company that looks at the
designing, manu-facturing, installing and commissioning of fabricated
stainless steel process and packaging equipments for the Indian
pharmaceutical companies. Since its inception in 1962, the company has
been operating in the Indian market with constant upgradation,
innovation and customization of its products. In 2010, the company
ventured into alliances with European companies, thus registering a
growth rate of about 20 percent.
In an interview with BioSpectrum
, Mr Karnik Parikh, director,
Pharmalab, throws light on the company’s achievements over the past one
year, global initiatives, product launches and future plans. Some
major achievements of Pharmalab in the last one year?
We manufactured hi-tech freeze dryers in technical collaboration with
Serail of France. Serail’s expertise in loading and unloading of vials
and bulk products gives comprehensive solution to achieve the latest
good manufacturing practice (GMP) standards and meet regulatory
requirements. We also brought out a state-of-the-art Aseptic Barrier
Technology from SKAN of Switzerland.
The isolation technology offered by SKAN is unique with
fully-integrated vaporized hydrogen peroxide sanitization facility,
built in the system.
Pharmalab also tied-up with FILTROX of Switzerland to bring high-tech
filtration systems, filter consumables and modules for the Indian
biotech, pharma and beverage industry. Manufacturing license for leaf
filters is under negotiation.
We partnered with Albet Hahnemuhle of Germany to bring laboratory
filter papers and consumables to the Indian market. This allowed us to
find markets in Europe and South American countries apart from Asian
markets. Our collaboration with Sterichem TBM of France was to
manufacture Ethylene Oxide Gas Sterilizers for the medical devices
market. All these alliances were possible due to better market demands,
innovative methods adopted by Indian pharma and biotech industry and
Indian companies were willing to offer indigenously manufactured
equipment to counter challenges posed by reputed international
favorable has the Indian life sciences market been for the company till
The Indian life sciences market has been quite favorable for
Pharmalab.We have been able to innovate and bring world-class
technology to India. We have been able to grow the business at the rate
of 15-20 percent barring 2008-09, which was the year of consolidation
as most companies held back investment in new projects. Our group
revenue for the current year is expected to be about $17 million (`80
been the performance of the company in the global markets, and what are
the new markets the company will focus on in the coming years?
Our export revenue growth was 30 percent in the last fiscal. We are now
exporting to almost 35 countries including European markets. Turkey,
Syria, Iran, Mexico, UAE, Kenya and Nigeria are also some of the growth
markets. We also export to our collaborators Serail and Sterichem in
France. We always look for new markets for growth. Our focus would now
be towards South American markets of Chile, Brazil, Argentina and
Mexico. North African countries like Tunisia and Algeria are also on
the new product launches in the pipeline, and what will be the Indian
We intend to launch many new products in the coming fiscal that include
TOC measuring device, range of hospital equipment, magnetic mixers of
latest standards, bag filtration systems, steam quality testing
devi-ces and ETO sterilizers for medical devices market.
any plans to venture into alliances and what criteria do you use for
striking an alliance?
We already have many alliances mostly with European companies. We are
planning to form alliances with Metenova of Sweden for magnetic mixers
and Letzner of Germany for water purification systems and TOC measuring
devices. We always look for a partner who can add value to our
operations in terms of technology transfer and market support.
the expansion plans and revenue target for Pharmalab in the next fiscal?
We have four manufacturing plants within the group and we are
constantly upgrading and manufacturing processes. Introducing new
welding, polishing and testing equipments are planned for next fiscal.
We are expecting a growth of 20 percent in the next fiscal with export
growing at 30 percent.